News8 min read
RFK Jr.'s peptide policy: what HHS changed for BPC-157 and five other peptides
HHS released a draft policy on October 28, 2026: it will not act against licensed compounding of BPC-157, TB-500, epitalon, KPV, MOTS-c, or semax under strict conditions. It is not FDA approval.
- regulatory
- HHS
- 503A
- compounding
- enforcement discretion

